An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

An Observational Chart Review Study to Describe the Real-world Outcomes and Use of Avelumab in Combination With Axitinib for Treatment of Patients With Advanced Renal Cell Carcinoma in the United Kingdom.

An observational chart review study to describe the real-world outcomes and use of avelumab in combination with axitinib for treatment of patients with advanced renal cell carcinoma in the United Kingdom.

Inclusion criteria

• Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
• Patients with a documented diagnosis of aRCC.
• Patients aged ≥18 years old at the index event date.
• Patient initiated on treatment with avelumab in combination with axitinib ( ≥1 dose) on or after 1st August 2019.

Exclusion criteria

• Patients meeting any of the following criteria will not be included in the study:
• Patients who received avelumab in combination with axitinib as part of a clinical trial
• Patients initiated on avelumab in combination with axitinib less than 12 months from the end of data collection.
• Patients who are known to have opted out of participation in any research